• HCPLive Podcasts

  • 著者： HCPLive.com
  • ポッドキャスト

HCPLive Podcasts

著者： HCPLive.com
無料で聴く

  • サマリー

  • Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.
    続きを読む 一部表示

あらすじ・解説

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.
政治・政府 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • HCPLive Under 5 Audio Recap: Week of 04/06

    HCPLive Under 5 Audio Recap: Week of 04/06
    2025/04/13
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for March 31-April 6, 2025:
    Cedars-Sinai Study Finds AI Tool Could Improve Care in Virtual Urgent Care Settings
    A Cedars-Sinai study suggests AI tools may enhance guideline adherence and decision-making quality in virtual urgent care, though clinician oversight remains essential.

    FDA Accepts Biologics License Application for ONS-5010 for Wet AMD
    The FDA has accepted a resubmitted BLA for ONS-5010, a proposed ophthalmic formulation of bevacizumab for wet AMD, advancing it toward potential approval.

    Socioeconomic Status Impacts Pediatric Preemptive Kidney Transplant Rates, Study Finds
    A retrospective study linked lower socioeconomic status to reduced access to preemptive kidney transplants in pediatric patients, underscoring ongoing disparities in care.

    FDA Clears Dexcom G7 15 Day CGM System
    The FDA has cleared the Dexcom G7 CGM system for 15-day use in adults, offering extended wear and continued improvements in diabetes monitoring technology.

    Icotrokinra Clears Skin Among 75% of Adolescents with Plaque Psoriasis
    New phase 3 data show once-daily icotrokinra improves skin clearance and maintains a favorable safety profile in adolescents with moderate-to-severe plaque psoriasis.
    続きを読む 一部表示
    4 分
  • HCPLive Under 5 Audio Recap: Week of 03/16

    HCPLive Under 5 Audio Recap: Week of 03/16
    2025/03/28
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for March 23-30, 2025:

    Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial

    Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.

    Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial

    Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.

    Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial

    Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.

    FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI

    The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.

    FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT

    The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.
    続きを読む 一部表示
    4 分
  • New Insight: Exploring ENCELTO for MacTel with Rich Small, CEO of Neurotech

    New Insight: Exploring ENCELTO for MacTel with Rich Small, CEO of Neurotech
    2025/03/24
    Welcome back to New Insight with Veeral Sheth, MD!

    Veeral Sheth, MD, is joined by Rich Small, the CEO of Neurotech, to discuss the historic approval of revakinagene taroretcel (ENCELTO) a groundbreaking encapsulated cell therapy for macular telangiectasia type 2 (MacTel). This approval marked the first and only FDA–approved treatment for MacTel, a neurodegenerative disease of the retina that can cause progressive and irreversible vision loss.

    Speaking with Sheth, Small recounted the long journey of Neurotech, which began in 2007, emphasizing the perseverance required to bring ENCELTO to market. He detailed his transition from Chief Financial Officer to CEO in 2016 and highlighted his team’s commitment, many of whom have been with the company for over a decade.

    The conversation explored the scientific foundation of ENCELTO, which uses genetically modified cells to release neurotrophic factors that protect photoreceptors in the retina. Unlike previous treatments that relied on best corrected visual acuity (BCVA) as a clinical endpoint, ENCELTO’s approval was enabled by advancements in imaging technology that allowed for direct measurement of photoreceptor health. Sheth and Small discussed the ideal patient profile for ENCELTO, noting that early intervention is key to preserving vision in MacTel patients.

    With ENCELTO’s approval secured, Small indicated the next step is widespread adoption, introducing ENCELTO.com as a patient service hub designed to streamline diagnosis, treatment, and access to care.

    #Ophthalmology #Podcast #RareDisease
    続きを読む 一部表示
    23 分

HCPLive Podcastsに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。